Pathogenesis of Diluted Hyponatremia and Therapeutic Strategy

doi:10.3969/j.issn.2095-1396.2020.01.011

Abstract

Abstract:

Hyponatremia is the most common electrolyte disturbance encountered in clinical practice，occurring in approximately 15%~30% of hospitalized patients. Hyponatremia carries a poor prognosis，being associated with significant mortality and morbidity. This review aims to be insight into diluted hyponatremia，lay theoretical foundation for the treatment，and provide supports for the discovery of new types of diuretics by sorting out and discussing the pathogenesis and management of diluted hyponatremia in cirrhosis，syndrome of inappropriate antidiuretic hormone secretion and heart failure.

Key words: diluted hyponatremia, cirrhosis, syndrome of inappropriate antidiuretic hormone secretion, heart failure, diuretics

Cite this article

WANG Shu-yuan, YANG Bao-xue. Pathogenesis of Diluted Hyponatremia and Therapeutic Strategy[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 54-64.

share this article

0
/ Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: http://actanp.hebeinu.edu.cn/EN/10.3969/j.issn.2095-1396.2020.01.011

http://actanp.hebeinu.edu.cn/EN/Y2020/V10/I1/54

References

1. Henry D A. Hyponatremia[J]. Annals of Internal Medicine, 2015, 163(3): ITC1-ITC1.

2. Frederik H Verbrugge, Paul Steels, Lars Grieten, et al. Hyponatremia in acute decompensated heart failure: depletion versus dilution[J]. J Am Coll Cardiol, 2015, 65(5): 480-492.

3. Amine Benmassaoud, Suzanne C Freeman, Davide Roccarina, et al. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2020, 1:CD013123.

4. D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients[J]. Aliment Pharmacol Ther, 2014, 39(10): 1180-1193.

5. Pere Gines, Monica Guevara. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management[J]. Hepatology, 2008, 48(3): 1002-1010.

6. Mark Sherlock, Eoin O'Sullivan, Amar Agha, et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage[J]. Clin Endocrinol (Oxf), 2006, 64(3): 250-254.

7. Maria Carlota Londono, Monica Guevara, Antoni Rimola, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation[J]. Gastroenterology, 2006, 130(4): 1135-1143.

8. Robert Schrier, Arroyo V, Mauro Bernardi, et al. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis[J]. Hepatology, 1988, 8(5): 1151-1157.

9. Laura Turco, Guadalupe Garcia-Tsao. Portal hypertension: pathogenesis and diagnosis[J]. Clin Liver Dis, 2019, 23(4): 573-587.

10. Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome[J]. Hepatol Int, 2018, 12(Suppl 1):122-134.

11. Adebayo D, Neong S F, Wong F. Ascites and hepatorenal syndrome[J]. Clin Liver Dis, 2019, 23(4): 659-682.

12. Florian Lang, Christoph Bohmer, Monica Palmada, et al. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms[J]. Physiol Rev, 2006, 86(4): 1151-1178.

13. David Pearce, Rama Soundararajan, Christiane Trimpert, et al. Collecting duct principal cell transport processes and their regulation[J]. Clin J Am Soc Nephrol, 2015, 10(1): 135-146.

14. Juan Pablo Arroyo, Dagmara Lagnaz, Caroline Ronzaud, et al. Nedd4-2 modulates renal Na+-Cl- cotransporter via the aldosterone-SGK1-Nedd4-2 pathway[J]. J Am Soc Nephrol, 2011, 22(9): 1707-1719.

15. DuVall M D, Zhu Sheng-he, Fuller C M, et al. Peroxynitrite inhibits amiloride-sensitive Na+ currents inXenopus oocytes expressing αβγ-rENaC[J]. American J Physiology-Cell Physiology, 1998, 274(5): C1417-C1423.

16. My N Helms, Yu Ling, Bela Malik, et al. Role of SGK1 in nitric oxide inhibition of ENaC in Na+-transporting epithelia[J]. Am J Physiol Cell Physiol, 2005, 289(3): C717-726.

17. Yang Lei, Gustavo Frindt, Florian Lang, et al. SGK1-dependent ENaC processing and trafficking in mice with high dietary K intake and elevated aldosterone[J]. Am J Physiol Renal Physiol, 2017, 312(1): F65-F76.

18. Al-Qusairi Lama, Basquin Denis, Roy Ankita, et al. Renal tubular SGK1 deficiency causes impaired K+ excretion via loss of regulation of NEDD4-2/WNK1 and ENaC[J]. Am J Physiol Renal Physiol, 2016, 311(2): F330-342.

19. Fenja Knoepp, Zoe Ashley, Daniel Barth, et al. Shear force sensing of epithelial Na(+) channel (ENaC) relies on N-glycosylated asparagines in the palm and knuckle domains of alphaENaC[J]. Proc Natl Acad Sci U S A, 2020, 117(1): 717-726.

20. Verney E B. Absorption and excretion of water the antidiuretic hormone[J]. The Lancet, 1946, 248(6430): 739-744.

21. Antoni F A. Vasopressin as a stress hormone[M]. Stress: Neuroendocrinology and Neurobiology, 2017: 97-108.

22. Eric Féraille, Alain Doucet. Sodium-potassium-adenosinetriphosphatase-dependent sodium transport in the kidney: hormonal control [J]. Physiological Reviews, 2001, 81(1): 345-418.

23. Detlef Bockenhauer, Daniel-G Bichet. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus[J]. Nat Rev Nephrol, 2015, 11(10): 576-588.

24. Saif A Muhsin, David Mount. Diagnosis and treatment of hypernatremia[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30(2): 189-203.

25. Tanja Vukicevic, Maike Schulz, Dorte Faust, et al. The trafficking of the water channel Aquaporin-2 in renal principal cells-a potential target for pharmacological intervention in cardiovascular diseases [J]. Front Pharmacol, 2016, 7(62): 23.

26. Wang W-L, Su S-H, Wong K Y, et al. Rab7 involves Vps35 to mediate AQP2 sorting and apical trafficking in the collecting duct cells[J]. American J Physiology-Renal Physiology, 2020.

27. Enno Klussmann, Grazia Tamma, Dorothea Lorenz, et al. An inhibitory role of Rho in the vasopressin-mediated translocation of Aquaporin-2 into cell membranes of renal principal cells [J]. J Biological Chemistry, 2001, 276(23): 20451-20457.

28. Katharina Schrade, Jessica Tröger, Adeeb Eldahshan, et al. An AKAP-Lbc-RhoA interaction inhibitor promotes the translocation of aquaporin-2 to the plasma membrane of renal collecting duct principal cells[J]. PLOS ONE, 2018, 13(1): e0191423.

29. Tanja Vukicevic, Christian Hinze, Sandrine Baltzer, et al. Fluconazole increases osmotic water transport in renal collecting duct through effects on Aquaporin-2 trafficking [J]. J Am Soc Nephrol, 2019, 30(5): 795-810.

30. Luo Ren-fei, Hu Shan, Liu Qiao-juan, et al. Hydrogen sulfide upregulates renal AQP-2 protein expression and promotes urine concentration[J]. FASEB J, 2019, 33(1): 469-483.

31. Fumiaki Ando, Eisei Sohara, Tetsuji Morimoto, et al. Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway[J]. Nat Commun, 2016, 7: 13636.

32. Birnbaumer M. Vasopressin receptors[J]. Trends in Endocrinology & Metabolism, 2000, 11(10): 406-410.

33. Lise Bankir, Daniel-G Bichet, Nils G Morgenthaler. Vasopressin: physiology, assessment and osmosensation[J]. J Intern Med, 2017, 282(4): 284-297.

34. Eric Feraille, Eva Dizin. Coordinated control of ENaC and Na+, K+-ATPase in renal collecting duct[J]. J Am Soc Nephrol, 2016, 27(9): 2554-2563.

35. Ishibashi K, Sasaki S, Fushimi K, et al. Immunolocalization and effect of dehydration on AQP3, a basolateral water channel of kidney collecting ducts[J]. Am J Physiol, 1997, 272(2 Pt 2): F235-241.

36. Soo Wan Kim, Veronika Gresz, Aleksandra Rojek, et al. Decreased expression of AQP2 and AQP4 water channels and Na,K-ATPase in kidney collecting duct in AQP3 null mice[J]. Biol Cell, 2005, 97(10): 765-778.

37. Marika Rudler, Maxime Mallet, Pilippe Sultanik, et al. Optimal management of ascites[J]. Liver Int, 2020, 40 (Suppl 1):128-135.

38. Chinese Society of Hepatology, Chinese Medical Association, Xu Xiao-yuan, et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis[J]. Hepatol Int, 2019, 13(1): 1-21.

39. Rossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al. Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study[J]. Ther Adv Med Oncol, 2019, 11:1758835919877725.

40. Reem A Mustafa, Alan S L Yu. Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?[J]. Clin J Am Soc Nephrol, 2018, 13(7):1107-1109.

41. Annarita Di Mise, Maria Venneri, Marianna Ranieri, et al. Lixivaptan, a new generation diuretic, counteracts vasopressin-induced aquaporin-2 trafficking and function in renal collecting duct cells [J]. Int J Mol Sci, 2019, 21(1).

42. Elsa Sola, Cristina Sole, Macarena Simon-Talero, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial[J]. J Hepatol, 2018, 69(6): 1250-1259.

43. Paolo Caraceni, Oliviero Riggio, Paolo Angeli, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial[J]. The Lancet, 2018, 391(10138): 2417-2429.

44. Cary H Paine, Raimund H Pichler. Treatment of hyponatremia in end-stage liver disease: new tools in the shed [J]. Am J Gastroenterol, 2018, 113(11):1728-1729.

45. Mauro Bernardi, Paolo Caraceni, Roberta J Navickis, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials[J]. Hepatology, 2012, 55(4): 1172-1181.

46. Rezwan Ahmed, Prasanna Santhanam, Yaser Rayyan. MELD-Na as a prognostic indicator of 30- and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt[J]. Eur J Gastroenterol Hepatol, 2015, 27(10): 1226-1227.

47. Bryan Oronsky, Scott Caroen, Arnold Oronsky, et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management[J]. Cancer Chemotherapy and Pharmacology, 2017, 80(5): 895-907.

48. San-E Ishikawa. Is exaggerated release of arginine vasopressin an endocrine disorder? Pathophysiology and treatment [J]. J Clin Med, 2017, 6(11): 102.

49. N Winn Seay, Ruediger W Lehrich, Arthur Greenberg. Diagnosis and management of disorders of body tonicity-hyponatremia and hypernatremia: core curriculum 2020 [J]. Am J Kidney Dis, 2020, 75(2): 272-286.

50. Mirjam Christ-Crain. Vasopressin and Copeptin in health and disease[J]. Rev Endocr Metab Disord, 2019, 20(3): 283-294.

51. Yamashita T, Yoshida M, Yamada H, et al. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm[J]. Intern Med, 2014, 53(8): 845-849.

52. Zhao Ning, Stephanie O Peacock, Chen Hao Lo, et al. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer[J]. Science Translational Medicine, 2019, 11(498): eaaw4636.

53. Taka-Aki Koshimizu, Aki Kashiwazaki, Junichi Taniguchi. Combined sodium ion sensitivity in agonist binding and internalization of vasopressin V1b receptors[J]. Sci Rep, 2016, 6: 25327.

54. Kozo Hamada, Katsuhiko Mikoshiba. IP3 receptor plasticity underlying diverse functions [J]. Annu Rev Physiol, 2020, 82(1): 151-176.

55. Andrea Kleindienst, Mark J Hannon, Michael Buchfelder, et al. Hyponatremia in neurotrauma: the role of vasopressin [J]. J Neurotrauma, 2016, 33(7): 615-624.

56. Kazuaki Nakamura, Gilberto Velho, Nadine Bouby. Vasopressin and metabolic disorders: translation from experimental models to clinical use[J]. J Intern Med, 2017, 282(4): 298-309.

57. Lynnette R Montgomery, Charles H Hubscher. Altered vasopressin and natriuretic peptide levels in a rat model of spinal cord injury: implications for the development of polyuria[J]. Am J Physiol Renal Physiol, 2018, 314(1): F58-F66.

58. Liu Chao, Chen Ying, Kang Yun-xiao, et al. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure[J]. J Pharmacol Exp Ther, 2011, 339(1): 203-209.

59. Deborah P Jones. Syndrome of Inappropriate Secretion of Antidiuretic Hormone and Hyponatremia[J]. Pediatrics in Review, 2018, 39(1):27-35.

60. Paul Grant, John Ayuk, Pierre-Marc Bouloux, et al. The diagnosis and management of inpatient hyponatraemia and SIADH[J]. Eur J Clin Invest, 2015, 45(8): 888-894.

61. Guy Decaux, Fabrice Gankam Kengne, Couturier B, et al. Actual therapeutic indication of an old drug: urea for treatment of severely symptomatic and mild chronic hyponatremia related to SIADH[J]. J Clin Med, 2014, 3(3): 1043-1049.

62. Helbert Rondon-Berrios, Srijan Tandukar, Mor Maria K, et al. Urea for the treatment of hyponatremia[J]. Clin J Am Soc Nephrol, 2018, 13(11): 1627-1632.

63. Alain Soupart, Michel Coffernils, Couturier B, et al. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH[J]. Clin J Am Soc Nephrol, 2012, 7(5): 742-747.

64. Andrew P Ambrosy, Gregg C Fonarow, Javed Butler, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol, 2014, 63(12):1123-1133.

65. Zhang Ying-ying, Johann Bauersachs, Harald F Langer. Immune mechanisms in heart failure[J]. Eur J Heart Fail, 2017, 19(11): 1379-1389.

66. Leonardo De Luca, Liviu Klein, James E Udelson, et al. Hyponatremia in patients with heart failure[J]. Am J Cardiol, 2005, 96(12A): 19L-23L.

67. Luigi Adamo, Cibele Rocha-Resende, Sumanth D Prabhu, et al. Reappraising the role of inflammation in heart failure[J]. Nat Rev Cardiol, 2020, 17: 269-285.

68. Yamashita Tomoya, Hayashi T, Yoshida N, et al. Gut microbial dysbiosis in heart failure- is it a future therapeutic target or not?[J]. Circ J, 2018, 82(6): 1507-1509.

69. Mark Luedde, Thorben Winkler, Femke-Anouska Heinsen, et al. Heart failure is associated with depletion of core intestinal microbiota[J]. ESC Heart Fail, 2017, 4(3): 282-290.

70. Takehiro Kamo, Hiroshi Akazawa, Wataru Suda, et al. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure[J]. PLoS One, 2017,12(3): e0174099.

71. Robert W Schrier. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone[J]. Am J Med, 2006, 119(7 Suppl 1): S47-53.

72. Steven R Goldsmith, Mihai Gheorghiade. Vasopressin antagonism in heart failure[J]. J Am Coll Cardiol, 2005, 46(10): 1785-1791.

73. Caterina Urso, Salvatore Brucculeri, Gregorio Caimi. Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications[J]. Heart Fail Rev, 2015, 20(4): 493-503.

74. Christophe Heymes, Jennifer K Bendall, Philippe Ratajczak, et al. Increased myocardial NADPH oxidase activity in human heart failure[J]. J Am Coll Cardiol, 2003, 41(12): 2164-2171.

75. De Vecchis R, Esposito C, Ariano C, et al. Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature[J]. Herz, 2015, 40(3): 423-435.

76. Renato De Vecchis, Claudio Cantatrione, Damiana Mazzei, et al. Vasopressin receptor antagonists for the correction of hyponatremia in chronic heart failure: an underutilized therapeutic option in current clinical practice?[J]. J Clin Med, 2016, 5(10):86.

77. Thomas A Zelniker, Eugene Braunwald. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review [J]. J Am Coll Cardiol, 2020, 75(4):435-447.

78. Austin Hsu, Duan Qi-ming, Sarah McMahon, et al. Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling[J]. J Clin Invest, 2020, 130(18), 10.1172/JCI133753.

79. Takuro Numaga-Tomita, Motohiro Nishida. TRPC channels in cardiac plasticity[J]. Cells, 2020, 9(2), DOI: 10.3390/cells9020454.

80. Steven R Goldsmith, James E Udelson, Mihai Gheorghiade. Dual vasopressin V1a/V2 antagonism: the next step in neurohormonal modulation in patients with heart failure?[J]. J Card Fail, 2018, 24(2): 112-114.

81. Nathan A Pinner, Carrie Oliphant, Jack P Hopkins. Use of conivaptan for the treatment of symptomatic hyponatremia in a patient with acute decompensated heart failure[J]. Am J Health Syst Pharm, 2010, 67(12): 1011-1015.

82. Robert A Fenton, Anneliese Flynn, Adetola Shodeinde, et al. Renal phenotype of UT-A urea transporter knockout mice[J]. J Am Soc Nephrol, 2005, 16(6): 1583-1592.

83. Jiang Tao, Li Ying-jie, Antia T Layton, et al. Generation and phenotypic analysis of mice lacking all urea transporters[J]. Kidney Int, 2017, 91(2): 338-351.

84. Ren Hui-wen, Wang Yan-hua, Xing Yong-ning, et al. Thienoquinolins exert diuresis by strongly inhibiting UT-A urea transporters[J]. Am J Physiol Renal Physiol, 2014, 307(12): F1363-1372.

85. Li Min, Zhao Yan, Zhang Shun, et al. A thienopyridine, CB-20, exerts diuretic activity by inhibiting urea transporters[J]. Acta Pharmacol Sin, 2020, 41(1): 65-72.

86. Marc O Anderson, Zhang Ji-cheng, Liu Yan, et al. Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B[J]. J Med Chem, 2012, 55(12): 5942-5950.

87. Lee Su-jin, Onur Cil, Elena Diez-Cecilia, et al. Nanomolar-potency 1,2,4-triazoloquinoxaline inhibitors of the kidney urea transporter UT-A1[J]. J Med Chem, 2018, 61(7): 3209-3217.

88. Onur Cil, Cristina Esteva-Font, Sadik Taskin Tas, et al. Salt-sparing diuretic action of a water-soluble urea analog inhibitor of urea transporters UT-A and UT-B in rats[J]. Kidney Int, 2015, 88(2): 311-320.

Metrics

Viewed

Full text

Abstract

Abstract
References
Related Articles
Recommended Articles
Metrics

TOP